211 related articles for article (PubMed ID: 34542155)
21. SHBG levels are associated with bone loss and vertebral fractures in patients with prostate cancer.
Varsavsky M; Reyes-García R; García-Martín A; González-Ramírez AR; Avilés-Perez MD; Muñoz-Torres M
Osteoporos Int; 2013 Feb; 24(2):713-9. PubMed ID: 22588185
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
23. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
24. Pitfalls in bone density monitoring in prostate cancer during anti-resorptive treatment.
Cheung YM; Ramchand SK; Grossmann M
Osteoporos Int; 2018 Jul; 29(7):1665-1670. PubMed ID: 29666893
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.
Saylor PJ; Morton RA; Hancock ML; Barnette KG; Steiner MS; Smith MR
J Urol; 2011 Aug; 186(2):482-6. PubMed ID: 21679977
[TBL] [Abstract][Full Text] [Related]
26. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
28. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
[TBL] [Abstract][Full Text] [Related]
29. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Diamond TH; Bucci J; Kersley JH; Aslan P; Lynch WB; Bryant C
J Urol; 2004 Aug; 172(2):529-32. PubMed ID: 15247721
[TBL] [Abstract][Full Text] [Related]
30. The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation.
Watanabe D; Kimura T; Yamashita A; Minowa T; Miura K; Mizushima A
Aging Male; 2020 Dec; 23(5):1158-1164. PubMed ID: 31959023
[TBL] [Abstract][Full Text] [Related]
31. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
32. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
33. The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.
Famili P; Cauley JA; Greenspan SL
J Urol; 2007 Mar; 177(3):921-4. PubMed ID: 17296376
[TBL] [Abstract][Full Text] [Related]
34. Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy.
Kim SH; Seong do H; Yoon SM; Choi YD; Song Y; Song H; Choi E
Eur J Oncol Nurs; 2016 Apr; 21():197-204. PubMed ID: 26522218
[TBL] [Abstract][Full Text] [Related]
35. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
36. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Szwedowski M; Tammela TL; Ke C; Leder BZ; Goessl C
J Urol; 2009 Dec; 182(6):2670-5. PubMed ID: 19836774
[TBL] [Abstract][Full Text] [Related]
37. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
38. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract][Full Text] [Related]
39. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
40. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu C; Chen W; Huang X; Lin R; Wu J; Zhang X
Clin Genitourin Cancer; 2018 Dec; 16(6):e1243-e1250. PubMed ID: 30146230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
